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ABSTRACT
TSPP is an anticancer poly-epitope peptide vaccine to thymidylate synthase, 
recently investigated in the multi-arm phase Ib TSPP/VAC1 trial. TSPP vaccination 
induced immune-biological effects and showed antitumor activity in metastatic 
colorectal cancer (mCRC) patients and other malignancies. Progression-free and 
overall survival of 41 mCRC patients enrolled in the study correlated with baseline 
levels of CEA, immune-inflammatory markers (neutrophil/lymphocyte ratio, CRP, ESR, 
LDH, ENA), IL-4 and with post-treatment change in p-ANCA and CD56dimCD16brightNKs 
(p < 0.04). A subset of 19 patients with activating k-ras mutations showed a different 
immune-inflammatory response to TSPP as compared to patients with k-ras/wt and a 
worse outcome in term of PFS (p = 0.048). In patients with k-ras/mut, inflammatory 
markers lost their predictive value and their survival directly correlated with the 
baseline levels of IL17/A over the median value (p = 0.01). These results provide 
strong hints for the design of further clinical trials aimed to test TSPP vaccination 
in mCRC patients. 
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INTRODUCTION
Thymidylate-synthase poly-epitope peptide 
(TSPP) is a 27-mer vaccine construct which contains 
the amino-acidic sequences of three known cytotoxic-
T-lymphocyte (CTL) epitopes with HLA-A(*)02.01 
amino-acid anchorage motifs (TS-1, TS-2, and TS-3) 
derived from the thymidylate synthase (TS) and showing 
promising antitumor activity in preclinical models [1–4]. 
TS is a cancer-associated target enzyme, critical for 
DNA replication and repair, commonly overexpressed 
in proliferating cancer cells, and inhibited by 5-FU 
metabolites and other anti-cancer drugs [1–3]. 
Several studies suggest that cytotoxic drugs like 
oxaliplatin, gemcitabine, 5-FU or cyclophosphamide, 
mAbs to EGFR and VEGF, as well as radiotherapy, may 
induce immunogenic cell death, and shape mCRC micro-
environmental conditions making the residual tumor tissue 
more sensitive to activated immune-effectors. On these 
bases, our group investigated the antitumor activity and the 
toxicity of the TSPP vaccination alone and in combination 
with 5-FU in HLA-A(*)02.01 (HHD) transgenic mice 
inoculated subcutaneously with TS-expressing EL-4/
HHD lymphoma cells. In these in vivo models, TSPP was 
able to elicit a specific CTL response without inducing 
autoimmunity or toxicity and showed a higher antitumor 
activity in combination with 5-FU [2]. Successively, TSPP 
was tested in a multi-arm phase Ib (TSPP/VAC-1) trial 
in metastatic pretreated cancer patients with different 
malignancies, including metastatic colorectal carcinoma 
(mCRC) and non-small-cell-lung-cancer (NSCLC) [5, 6]. 
The trial investigated the effects of TSPP vaccination 
alone (arm-A) or associated with granulocyte macrophage-
colony-stimulating-factor (GM-CSF) and interleukin-2 
(IL-2) (arm-B) [5, 7], or in concomitant (Arm-C/DL1-3) 
or sequential (arm-C/DL0) combination with a previously 
characterized [5, 6] chemo-immunotherapy regimen with 
gemcitabine, oxaliplatin, levo-folinic acid (FA) and bolus/
infusional 5-FU followed by IL-2 and GM-CSF (GOLFIG 
regimen) [6, 8–11]. The study enrolling 50 patients (12 in 
the arm A, 9 in the arm B, and 29 in the arm C) showed 
that TSPP is safe (MTD was not achieved), exerts immune-
modulating effects and produces self-limiting auto-immunity 
signs in all of the experimental arms. Specifically, TSPP 
vaccination elicited TS-specific-T cell response and was 
associated to a progressive rise in serum auto-antibodies 
[Anti-nuclear anti-bodies (ANA), anti-extractable nuclear 
antigen (ENA), anti-neutrophil cytoplasmic antibodies/
anti-proteinase-3 (pANCA), and anti-myeloperoxidase 
(cANCA)] [5, 6]. This study reported preliminary evidence of 
TSPP antitumor activity on mCRC patients representing the 
majority of patient population [5, 6] and granting the rationale 
to design further phase II trials. We, therefore, attempted to 
identify potential biomarkers predictive of treatment response 
to TSPP by carrying -out a retrospective analysis on a cohort 
of 41 mCRC patients enrolled in the TSPP/VAC1 trial.
RESULTS 
Demographics, chemo-immunotherapy, peptide 
vaccination and dose-escalation
Forty-one mCRC patients, enrolled in the TSPP/
VAC1 multi-arm phase-Ib trial between May 2011 and July 
2013, were considered for this study. TSPP resulted safe 
and able to induce immune-modulatory activity, including 
changes in serum levels of multiple inflammatory 
markers (CRP, ESR, LDH/NV), Auto-antibodies (ANA, 
ENA, p-ANCA, and c-ANCA) and TSPP-specific CTL 
precursors’ frequency. Th1/Th2/Th17 cytokine profile, 
blood cell counts, peripheral lymphocyte subsets, DCs and 
MDSCs showed minimal difference among the three study 
arms. The population of mCRC patients enrolled in the 
trial was homogeneous in term of clinical and immune-
biological features and previous treatments (Table 1). All 
patients were required to present high tumor expression of 
TS at baseline, while a subgroup of19 patients (46.3%) also 
presented an activating k-ras mutation. 
Pathology study 
An immune-histochemical primary tumor analysis 
in patients bearing wild type k-ras (k-ras/wt) (22 cases) 
or activating K-ras mutations (K-ras/mut) (19 cases) prior 
vaccination, revealed no significant difference concerning 
TS expression (score of expression: 30 for overall, 28 for 
K-ras/wt and 33 for K-ras/mut ) (Figure 1A) and tumor 
infiltration by CD4+, CD8+, CCR7+ T cells and Tregs 
(Figure 1B). A lower infiltration score of inflammatory 
CD15+cells was conversely found in patients with k-ras/
mut (Figure 1B). It was also observed a significant 
post-treatment decrement in TS expression in the tumor 
samples of 10 patients undergone biopsy or surgery after 
multiple TSPP vaccinations [baseline versus (vs.) post-
treatment values: 30.2 ± 4.69 vs. 3.7 ± 0.98; P = 0.011). 
Other post-treatment correlations (tumor infiltration by 
immune-cell subsets and k-ras stratification) could not be 
performed for inadequacy of biological material.
Immune-monitoring
Our immune-biological analysis did not reveal 
differences between patients with k-ras/wt and k-ras/mut, 
in term of inflammatory markers, peripheral immune-cell 
subsets and cytokine immune-profile at baseline (Figure 
1C–1F). There was a general rise in CRP, c-ANCA, 
p-ANCA, ENA, and TregS and Tcms, IFNɣ, IL12/A, and 
IL10 in the whole patients’ population (Figure 1D–1F). On 
the other hand, patients with k-ras/mut showed greater and 
progressive rise in the peripheral levels of IFNγ, TNFα, 
and IL17/A, a significant increase in peripheral Tcms, and 
Tregs, and no change in the levels of cANCA and ENA, 
which conversely, resulted largely increased in patients 
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Table 1: Demographic, clinical and molecular pathology characteristics of the patients enrolled in the clinical trial
CODE Sex ECOG Metastatic sites Previous treatment lines K-ras HLA 
Treatment 
courses MANT
Type of 
response
MFA/A/DL1 F 0 Liver, lung 11 Wt A2 3 Na SD
RAA/A/DL1 F 0 Peritoneum, nodes 7 Wt A2 3 Na PD
ASA/A/DL1 M 0 Liver, Lung 3 Wt A2 3 Na SD
LVA/A/DL2 M 0 Liver, Lung, nodes 7 Wt A11 6 Na SD
SGA/A/DL2 M 0 Peritoneum, nodes 4 Wt A25 6 Na SD
ZSA/A/DL3 F 0 Nodes, Adrenal 3 Wt A2 48 Na PR
PNA/A/DL3 F 0 Lung, bones 3 Mut A1 3 Na SD
SNA/A/DL3 M 2 Liver, lung 3 Mut A2 3 Na PD
GL/B/DL2 F 0 Liver, abdomen 3 Mut A24 3 Na PD
PP/B/DL2 F 0 Lung, liver abdomen 3 Wt A2 3 Na SD
FG/B/DL2 M 0 Abdomen, nodes 3 Wt A24 3 Na PD
MM/B/DL3 M 1 Lung, liver abdomen 3 Mut A1 3 Na SD
LM/C/DL1 F 2 Peritoneum, lung, liver 2 Mut A24 7 2 SD
CV/C/DL1 M 1 Peritoneum, lung, liver 6 Mut A3 6 0  PD
BF/C/DL1 M 2 Peritoneum, lung, liver 3 Mut A11 3 0 PD
CL/C/DL2 F 0 Peritoneum, nodes 3 Mut A2 12 1 PD
FA/C/DL2 F 2 Colon, lung, liver 6 Wt A11 11 0 SD
SA/C/DL2 M 0 Lung, liver, nodes 5 Wt A2 12 2 PR
SS/C/DL3 F 0 Brain, lung, liver, nodes 5 Mut A23 12 3 PR
BA/C/DL3 F 1 Colon, lung, liver, nodes 2 Mut A2 11 0 SD
SA/C/DL3 F 2 Peritoneum, lung, liver 5 Mut A2 12 0 PD
DA/C/DL3 F 2 Peritoneum, lung, liver 4 Mut A1 10 0 PD
MP/C/DL3 M 1 Peritoneum, lung, liver 6 Mut A2 6 0 SD
PM/C/DL3 M 1 Peritoneum, lung, liver 2 Mut A11 12 3 SD
MU/C/DL3 F 1 Soft tissue, nodes 2 Wt A24 12 14 SD
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with k-ras/wt (Figure 1D–1F). No significant differences 
were recorded for NEUTR, LINF, CD4+, CD8+,and Tems.
Patients’ outcome correlations
The impact of these inflammatory and immunological 
parameters (Table 2) on the outcome of TSPP vaccinated 
patients was also investigated. Altogether, these patients 
presented an OS of 14.902 ± 2.575 (95% CI 9.85–19.85) 
months, with 13 out of 41 cases surviving more than 12 
months. In our series, PFS and OS were inversely correlated 
with the baseline performance status (ECOG score) and 
CEA levels. Patients with k-ras/mut presented a worse 
outcome with shorter PFS (Table 3) and no differences in 
OS. We did not find significant differences when PFS and 
OS were correlated with the number of previous treatment 
lines, age, gender, HLA-A(*)02.01 haplotype, and TS-and 
immune-cell tumor infiltration scores, TS score change 
after treatment (data not shown). 
Patients in the arm C/DL-0 (GOLFIG chemo-
immunotherapy followed by TSPP vaccine) showed the 
longest survival over the other treatment groups [arm C/
DL0 vs arm A, B, and C/DL 1-3; log Rank test, p = 0.03 
and Breslow (Generalized Wilcoxon) test, P = 0.021] even 
though these results should be taken cautiously for the very 
small statistical sample (Figure 2B). Our statistical analysis 
also revealed that patients’ PFS and OS correlated with 
lower baseline levels of neutrophils, NLR, CRP, ESR, LDH/
NV, ENA and IL4. PFS and OS also correlated with no post-
treatment increases (FBV > 1) of the same inflammatory 
markers. Finally, a prolonged survival was also recorded 
in patients presenting a treatment-related increase (FBV > 
1) of pANCA and highly cytotoxic NK (CD56dimCD16brigth) 
cells (Table 4). On the overall population, we were unable 
to find any significant correlation of either PFS or OS with 
the baseline values and post-treatment changes of TS-
specific CTL precursor frequency, TNFα, IL12p70, IFNγ, 
IL10,IL17, CD4+, CD8+,Tcms,Tems, Tregs, DCs, MDSCs 
(Table 4 and data not shown).
Predictive markers in patients who received 
TSPP ± cytokines and TSPP + GOLFIG chemo-
immunotherapy 
Then, the predictive values of these inflammatory 
and immunological parameters was separately 
PA/C/DL3 M 1 Peritoneum, lung, liver 7 Wt A2 11 3 PR
CA/C/DL3 M 2 Peritoneum, lung, liver 3 Mut NA 6 0 PD
BG/C/DL3 F 0 Peritoneum, lung, liver 3 Wt A2 10 8 SD
NR/C/DL3 F 2 Peritoneum, lung, liver 2 Mut A2 3 0 PD
SR/C/DL0 M 0 Lung, liver 3 Wt A23 12 5 SD
DG/C/DL0 F 0 Lung, liver 3 Wt A33 10 5 PR
BL/C/DL0 F 0 Lung, liver 2 Wt A3 10 9 SD
ML/C/DL0 F 0 Peritoneum, lung, liver 2 Mut A2 10 9 SD
VP/C/DL0 M 1 lung, liver 2 Wt A2 7 1 PD
PG/C/DL0 M 1 lung, liver 2 Wt A24 9 12 SD
SA/C/DL0 M 2 Peritoneum, lung, liver 3 Wt A1 7 0 PD
MA/C/DL0 M 0 lung, liver 2 Mut A1 9 32 PR
PA/C/DL0 M 0 lung, liver 2 Wt A3 11 14 PR
DL/C/DL0 F 0 Peritoneum, lung, liver  3 Wt A2  9 4 SD
VC/C/DL0 M 0 Peritoneum, lung, liver 2 mut A23 10 7 PR
PA/C/DL0 F 1 Peritoneum, lung, liver 3 Wt A23 9 4 SD
Legend: ECOG, Eastern Cooperative Oncology Group performance status; Wt, Wild type; Mut, Mutated; SD, Stabilized Disease; PR, Partial Response; 
PD, Progressive Disease; MANT, Maintainance Therapy duration in months; Na; not achieved.
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investigated in patients receiving TSPP vaccine ( ± 
cytokines) alone or together with cytotoxic drugs. The 
two groups did not show difference in term of survival 
[arm A + B vs C/DL0 + C/DL1-3: 13.49 ± 4.89 (95% 
CI 3.92–23.07) vs. 14.62 ± 2.45 (95% CI 9.82–19.42); 
p = 0.29] (Figure 2A). On the other hand, those patients 
who received the sequential treatment (arm C/DL0) 
with GOLFIG followed by TSPP vaccination showed 
the longest survival over the other groups (p = 0.03) 
(Figure 2B). First of all, a longer survival in patients with 
lower NLR, independently by the treatment arm, was 
confirmed (p = 0.016) (Figure 2C–2D). We also reported 
that a lower Treg expression at baseline showed a trend 
to longer survival in both groups (arm A + arm B: p = 
0.062) (arm C DL1-3 and DL0: p = 0.088) (Figure 2E–
2F). Moreover, we observed that higher IL17/A levels 
at baseline correlated with longer survival in the group 
of patients enrolled in the arm C (DL0-3: p = 0.017) 
only, with no correlation in the other group (arm A + B: 
p = 0.253) (Figure 2G–2H). In order to identify specific 
inflammatory immunological signatures predictive of 
response to TSPP vaccination we assembled and tested 
an inflammation-score. It was composed by assigning 
an arbitrary value to specific inflammatory parameters 
at baseline. Each parameter (ESR, CPR and LDH/NV) 
was categorized as zero, when it was < the specific 
median value and 1 if it was ≥ the median value. The 
inflammatory score derived from the sum of the three 
Figure 1: (A) Immuno-histochemical analysis of TS expression in the primary tumor of 41 mCRC patients enrolled in the TSPP/VAC-
1trials [All patients (overall), patients with k-ras wt (wt-k-ras) and patients with mutated k-ras (mut-k-ras)]. Results are expressed as 
number of positive cells per HPF ( ± SE). No difference in TS expression was detected between the two subsets of patients. (B) Immuno-
histochemical analysis of tumor infiltrating T cells expressing FoxP3 (Treg), CCR7 (Tcm/em), CD4, or CD8 and inflammatory cells expressing 
CD15. This analysis was carried out in the primary tumor of 41 mCRC patients who received TSPP vaccine [ ], whose 22 with k-ras wt [□] 
and 19 with mutated k-ras [■]. Results are expressed as number of positive cells per HPF ( ± SE). No differences were detected between 
the two subsets of patients with exception of CD15+ cells, which showed a reduced expression in patients with k-ras mut (P = 0.046), 
Asterisk (*) represents statistically significant difference. (C) Cytokine Multiplex analysis- Evaluation of baseline serum levels of IFNɣ, 
TNFα, IL12p70, IL17/A, IL10, IL4 of 41 mCRC patients who received TSPP vaccine 41 mCRC patients who received TSPP vaccine [ ], 
wt [□] and 19 with mutated k-ras [■]. Results are pg/ml ( ± SE). No differences were detected between the two subsets of patients at 
baseline. (D) Evaluation of fold change to baseline values of serum levels of IFNɣ, TNFα, IL12p70, IL17/A, IL10, and IL4 of 41 mCRC 
patients who received TSPP vaccine [ ], whose 22 with k-ras wt [□] and 19 with mutated k-ras [■]. Results are expressed as fold induction 
relative to baseline indicated as 1 ( ± SE). Asterisk (*) represents statistical significance to between k-ras mut vs k-ras wtpatients (P < 0.05); 
hashtag (#) represents statistical significance to baseline value (P < 0.05). (E) Evaluation of fold change to baseline values of Neutrophils, 
lymphocytes, CRP, cANCApANCA and ENA of 41 mCRC patients who received TSPP vaccine [ ], whose 22 with k-ras wt [□] and 19 
with mutated k-ras [■]. Results are expressed as fold induction relative to baseline indicated as 1 ( ± SE). Asterisk (*) represents statistical 
significance to between k-ras mut vs k-ras wt patients (P < 0.05); hashtag (#) represents statistical significance to baseline value (P < 0.05). 
(F) Flow cytometry- Evaluation of fold change to baseline levels of peripheral blood cells expressing the following phenotypes: CD3+CD4+, 
CD3+CD8+, or CD8+CD45Ra-CCR7+ (Tcms), CD8
+CD45Ra-CCR7- (Tems), CD3
+CD4+FoxP3+ (Tregs), CD3
+CD56dimCD16bright(cytotoxic NK), 
and myeloid derivative suppressive cells (MDSCs). This analysis was performed on 41 mCRC patients who received TSPP vaccine [ ], 
whose 22 with k-ras wt [□] and 19 with mutated k-ras [■]. Results are expressed as fold induction relative to baseline indicated as 1 ( ± 
SE). Asterisk (*) represents statistical significance to between k-ras mut vs k-ras wt patients (P < 0.05); hashtag (#) represents statistical 
significance to baseline value (P < 0.05).
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parameters’ values. When a statistical analysis was carried 
out a low inflammation-score (<2) was highly predictive 
of longer survival in patients enrolled in arm A and B 
[high vs. low score (<2) high vs. low score: p = 0.049) 
while it showed no significance in patients enrolled in the 
arm C (high vs. Low score: p = 0.199) (Figure 2B). 
Predictive markers in mCRC patients with 
k-ras/wt and k-ras/mut who received TSPP 
vaccine
Finally our analysis revealed that either 
inflammatory or immunological parameters, and 
independently by the treatment arm, showed substantial 
differences when respectively, correlated with OS in 
patients bearing k-ras/mut. 
In particular, in the latter group of patients the 
predictive value of ESR, CRP, LDH/NV and ENA levels 
at baseline was lost in term of survival.
Additionally, we found the OS of patients with 
k-ras/wt, and not those with k-ras/mut, was specifically 
correlated with baseline IL12/p70 levels lower than 
the median value (p = 0.034), while the OS of patients 
with k-ras/mut, and not those with k-ras/wt, specifically 
correlated with the baseline IL17/A levels over the median 
value (p = 0.01) (Table 5 and Figure 3).
DISCUSSION
The results of the TSPP/VAC 1 trial suggested that 
TSPP vaccination is safe, induces immune-modulatory 
effects and exerts antitumor activity in 41pretreated mCRC 
patients (third/fourth treatment line), who showed a PFS 
and OS of 6.9 and 14.9 months, respectively. These results 
can be considered very encouraging at the light of the fact 
that Regorafenib, the multi-kinase inhibitor currently 
recommended for salvage treatment of pretreated mCRC, is 
associated to a PFS and OS, respectively of 2 and 6.4 
months, with significant adverse events and very high costs 
[12]. These results in mCRC patients may also be of interest 
considering that mCRC-immunotherapy has been a 
dynamic field of investigation for more than 30 years with 
controversial results in term of antitumor activity [13, 14]. 
In fact, results of several immunotherapy trials have shown 
that it is possible to use different antigen vectors to trigger 
an efficient T cells response to tumor associate antigens 
such as CEA, MUC-1, k-ras/mut in mCRC patients [13]. 
Nevertheless, even in the presence of a significant 
treatment-induced T cell response, none of these agents has 
been able to improve the outcome of these patients [13]. 
Several reasons have been advocated to explain these 
negative results, including the poor immunogenicity of the 
target antigens and/or failures in the delivery constructs, 
Table 2: Immunophenotypic characteristics and serum molecular markers and auto-antibodies of the patients
Neu Lymph NLR CRP ESR LDH/N 
Overall
3650 
(278,2)
1571
(118,4)
2,609
(0,22)
2,434
(0,4)
68 (5.3) 1,481
(0,16)
Wt-k-ras
3456
(507,9)
1581
(41,7)
2,512
(0,45)
1,832
(0,5)
56,5 (6.8) 1,365
(0,26)
Mut-k-ras
3939
(368,7)
1636
(171,7)
2,748
(0,3)
3,104
(0,8)
68 (7.8) 1,601
(0,2)
CEA c-ANCA p-ANCA ENA
Overall
122,5 
(211.8)
0,921
(0,1)
0,688
(0,08)
0,324
(0,04)
Wt-k-ras
180.5 
(383.3)
1,086
(0,1)
0,729
(0,21)
0,337
(0,02)
Mut-K-ras
122,5 
(127.8)
0,763
(0,08)
0,625
(0,08)
0,326
(0,05)
CD4+ CD8+ Treg Tcm Tem c-NK MDSCs
Overall 40,1 (2,6) 26,9 (1,7) 3,2 (0,44) 6,3 (1,39) 40,3 (3,26) 9.63 (3,36) 3.95 (1,97)
Wt-k-ras 38,2 (1,8) 25,7 (2,1) 3,2 (0,05) 4,7 (0,09) 44,7 (2,2) 7.57 (4,45) 4.47 (1,47)
Mut-K-ras 44,2 (3,3) 29,6 (2,8) 3,5 (0,7) 8,57 (2,67) 37,2 (5,06) 11.7* (4,13) 3.55 (2,1)
     *0.030913  
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occurrence of immune-suppressive cell lineages (Tregs, 
MDSCs, M2-macrophages, etc.), the resistance of CCR 
cells to the immune-effectors, the interference of multiple 
immune-checkpoint inhibitors, and finally, a tumor-
protective-microenvironment associated with CRC [13]. 
The latter points in particular have been associated to 
chronic inflammation, neo-angiogenesis and hypoxia, 
infiltration by Tregs, MDSCs, and other immune-suppressive 
cell lineages expressing PDL-1 and PDL-2 [15]. More 
recent immunotherapy approaches involving immune-
checkpoint blockade, successful in the treatment of other 
solid tumors, have instead achieved deluding therapeutic 
results in mCRC patients [16–20]. In fact, mAbs to CTLA-
4 resulted completely inactive [15–16], while mAbs to 
PD-1/PDL1 immune-checkpoint have shown antitumor 
activity only in a subset of patients with deficient mismatch 
repair (dMMR). In the latter case, it has been hypothesized 
that the dMMR status increases the burden of neo-antigens 
that elicit a very proficient CTL response with potential 
antitumor activity susceptible to PD-1/PDL1 axis, and 
consequently, to mAb blockade [16]. All together, these 
results clearly suggest that immune-checkpoint blockade 
requires the presence of highly cytotoxic CTLs educated to 
destroy mCRC cells expressing critical antigens, eventually 
inhibited in the tumor tissue throughout PD-1 axis, as main 
mechanism of immune-escape. In this context, the use of 
TSPP vaccination to elicit a TS specific CTL response prior 
scheduling PD1/PDL-1blockade could be a very successful 
treatment strategy to take in consideration for mCRC 
patients. Additionally, the results of several studies suggest 
that cytotoxic drugs like oxaliplatin, gemcitabine, 5-FU or 
cyclophosphamide, mAbs to EGFR and VEGF, as well as 
radiotherapy, may induce immunogenic cell death, and 
shape mCRC micro-environmental conditions making the 
residual tumor tissue more sensitive to activated immune-
effectors [17–20]. On the other hand, previous clinical 
Table 3: Statistical evaluation of the correlation between clinical/tumor-associated markers and the clinical outcome 
of the patients
Comparative marker Cut-off value Number of patients Months ± SD Endpoint P value
ECOG ≤1
>2
29
10
9,31 ± 2,27
2,41 ± 0,43
PFS <0.001
ECOG ≤1
>2
29
10
17,04 ± 2,97
3,91 ± 0,74
OS <0.001
CEA ≤ median value
>median value
19
17
11,05 ± 3,36
4,41 ± 0,78
PFS 0.189
≤ median value
>median value
19
19
19,10 ± 4,19
7,42 ± 1,14
OS 0.021
Sex Male
Female
18
21
5.8 ± 7.2
8.05 ± 11.6
PFS >0.25
Male
Female
18
21
11.44 ± 10.1
11.8 ± 12.2
OS > 0.25
Age (years) <50
≥50
7
32
3.71 ± 2.28
7.75 ± 10.59
PFS >0.25
<50
≥50
7
32
10.7 ± 5.43
11.8 ± 12.11
OS >0.25
HLA-A2 Positive
Negative
15
20
7,46 ± 2,98
7,10 ± 2,00
PFS 0.764
Positive
Negative
15
20
12,16 ± 3,35
13,70 ± 2,93
OS 0.684
K-ras status Wild Type
Mut
22
19
8,77 ± 2,29
4,68 ± 1,58
PFS 0.050
Wild Type
Mut
22
19
15,98 ± 3,35
8,64 ± 2,31
OS 0.160
Legend: ECOG, Eastern Cooperative Oncology Group performance status; CEA, Carcino-Embryonic Antigen; Mut, 
Mutated.
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results of our group on the GOLFIG regimen have shown 
that a rationale combination of chemotherapy and immune-
adjuvant cytokinesis are really capable to improve both PFS 
and OS in mCRC [8–11]. The GOLFIG regimen has been 
designed to mimic an in vitro procedure to generate very 
efficient CCR-specific CTLs from human PBMCs and in 
parallel to shape the residual tumor to become more 
susceptible to the immune-effector activity [8, 13, 21]. In 
preclinical models, this multi-drug regimen was able to 
induce immunogenic cell death in CRC cells, with massive 
release of TAAs in a context of danger signal and cross-
priming, which in turn was able to trigger a multi-antigen 
specific T cell response with potent antitumor activity 
[8, 21]. In line with these preclinical results, two 
consecutive phase II and phase III trials showed that the use 
of this regimen in mCRC patients, elicits a CEA/TS specific 
T cell response, increases the amount of peripheral and 
central Tcms, and in parallel decreases the score of tumor 
infiltrating Tregs [9–11]. Sixteen percent of the mCRC 
patients receiving this treatment, presented autoimmunity, 
an event which resulted strongly predictive of prolonged 
PFS and survival [10]. Based on these immune-adjuvant 
and immune-shaping properties, the GOLFIG regimen was 
investigated in concomitant and sequential combination 
with TSPP in the arm C of TSPP/VAC-1 trial in mCRC 
patients (arm C/DL1-3 and C/DL0, respectively). Even 
though the three arms were not designed on comparative 
setting, those patients who had received TSPP vaccination 
after multiple GOLFIG courses (arm C/DL0) showed a 
very promising outcome, with a PFS and OS of 7 and 16 
months, respectively [5, 6]. In line with these data, the 
results of our study in mCRC patients undergone TSPP 
vaccination suggested that the number of previous 
treatments, age, gender, treatment arm (A, B or C), 
HLA-A(*)02.01 haplotype, TS levels and TIL immune-
phenotype in the tumor, at baseline, were not able to 
influence the outcome of these patients. On the other hand, 
a good performance status and lower CEA levels at 
baseline, representative of a smaller tumor burden, were 
associated to a better outcome. Additionally, the presence of 
an activating K-ras mutation was associated to a worse 
outcome in term of PFS and to a trend to a worse survival. 
Figure 2: Evaluation of predictive markers in patients who received TSPP ± cytokines and TSPP + GOLFIG chemo-
immunotherapy. (A) Overall survival in mCRC patients who received TSPP ± cytokines (Arm A + B) vs those who received TSPP + 
GOLFIG regimen (Arm C/DL + Arm C/DL1-3). (B) Overall survival in mCRC patients enrolled in the different treatment arms (Arm A vs 
B vs C/DL0 vs C/DL1-3). (C) Influence of the inflammation score (NLR, PCR, LDH) on the survival of mCRC patients who received TSPP 
± cytokines (Arm A and B). (D) Influence of the inflammation score (NLR, PCR, LDH) on the survival of mCRC patients who received 
TSPP + GOLFIG regimen (Arm C/DL0-3). (E) Influence of peripheral Tregs’ baseline levels on the survival of mCRC patients who received 
TSPP ± cytokines (Arm A and B). (F) Influence of peripheral Tregs’ baseline levels on the survival of mCRC patients who received TSPP 
+ GOLFIG regimen (Arm C/DL0-3). (G) Influence of IL17/A baseline levels on the survival of mCRC patients who received TSPP ± 
cytokines (Arm A and B) (H) Influence of IL17/A baseline levels on the survival of mCRC patients who received TSPP + GOLFIG regimen 
(Arm C/DL0-3). Asterisk (*) represents statistical significance between the arms (P < 0.05). 
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Table 4: Correlation between immunological characteristics and inflammation serum markers levels and PFS and OS
Comparative marker Cut-off value
Number 
of 
patients 
Months ± SD Endpoint P value
NLR (neutrophil to 
lymphocytes ratio)
≤median value
>median value
20
20
11,10 ± 3,18
3,80 ± 0,59 PFS 0.010
≤median value
>median value
20
20
19,01 ± 3,97
7,40 ± 1,04 OS 0.011
NeutrophilFBV ≤1>1
25
14
10,16 ± 2,57
3,07 ± 0,67 PFS 0.003
≤1
>1
25
14
18,51 ± 3,38
5,85 ± 1,29 OS 0.001
CRP ≤median value
>median value
20
20
11,25 ± 3,17
3,65 ± 0,54 PFS 0.005
≤median value
>median value
20
20
19,75 ± 4,10
7,40 ± 1,48 OS 0.002
CRP FBV ≤1>1
6
6
5,33 ± 1,05
12,83 ± 3,59 PFS 0.019
≤1
>1
6
6
10,66 ± 2,00
22,04 ± 3,81 OS 0.027
ESR ≤median value
>median value
19
18
10,15 ± 3,14
5,27 ± 1,69 PFS 0.090
≤median value
>median value
19
18
18,92 ± 3,69
7,52 ± 1,97 OS 0.002
LDH/LDHNR ≤median value
>median value
19
19
10,84 ± 3,36
4,42 ± 0,80 PFS 0.106
≤median value
>median value
19
19
19,64 ± 3,88
6,60 ± 0,84 OS 0.001
ENA ≤median value
>median value
20
17
18,47 ± 3,78
8,58 ± 2,11 OS 0.011
cANCA ≤median value>median value
18
18
16,66 ± 3,72
12,30± 2,99 OS 0.510
pANCA ≤median value>median value
16
18
18,37 ± 4,05
11,57 ± 2,89 OS 0.17
pANCA 
FBV 
≤1
>1
8
13
6,12± 1,67
16,76 ± 4,22 OS 0.039
IFN ɣ ≤median value
>median value
16
16
11,68 ± 3,07
18,31 ± 3,81 OS
0.154
IL12p70 ≤median value
>median value
17
17
18,05 ± 4,24
10,91 ± 1,98 OS 0.250
IL17 ≤median value
>median value
18
18
10,16 ± 2,57
17,83 ± 3,36 OS 0.056
IL10 ≤median value>median value
16
16
15,19 ± 4,12
11,77 ± 1,92 OS 0.747
IL4 ≤median value
>median value
18
16
10.33 ± 2.80
18.99 ± 3,55 OS 0.028
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Concerning the immune-biological monitoring, the best 
outcome in patients with lower systemic inflammatory 
baseline profile (neutrophil counts, NLR, CRP,ESR, LDH/
LDHNV, and ENA) and higher baseline levels of IL-4, 
which may promote occurrence of auto-antibody-driven 
autoimmunity, was found [22, 23]. The best outcome was 
also detected in vaccines with increase in pANCA, an auto-
antibodies, whose presence is suggestive of autoimmunity 
TEM ≤median value
>median value
19
17
13,25 ± 2,30
15,86 ± 4,46 OS 0.887
TCM
≤median value
>median value
18
18
12,05 ± 3,42
15,64 ± 2,88 OS 0.149
TREG
 ≤median value
 >median value
17
19
13,94 ± 3,77
14,34 ± 2,84 OS 0.833
Legend: PFS, progression-free survival; OS, overall survival; NeutrophilFBV, Neutrophil fractional blood volume; CRP, 
C-reactive protein; ESR, erythrocyte-sedimentation rate; LDH/LDHNR, Lactate Dehydrogenase/Lactate Dehydrogenase 
Normal Range; ENA, anti-extractable nuclear antigen; cANCA, anti-neutrophil cytoplasmic antibodies/ anti-myeloperoxidase; 
pANCA, anti-neutrophil cytoplasmic antibodies/anti-proteinase-3; IFN ɣ, Interferon gamma; IL, interleukin, TEM, effector/
memory T lymphocytes; TCM, central memory T lymphocytes; TREG, regulatory T lymphocytes.
Table 5: Inflammatory predictive markers/k-ras mutational status correlation with clinical outcome of the patients
Subgroup Comparative marker Cut-off value
Number of 
patients Months ± SD Endpoint P value
k-ras/wt Neutrophil Count ≤median value
>median value
10
9
24,11 ± 6,21
10,22 ± 2,72
OS 0.050
NLR ≤median value
>median value
12
8
23,06 ± 5,37
8,25 ± 1,57
OS 0.020
CRP ≤median value
>median value
11
9
23,26 ± 5,62
9,44 ± 2,65
OS 0.023
ENA ≤median value
>median value
9
10
24,46 ± 5,55
10,90 ± 3,36
OS 0.029
IL12 p70 ≤median value
>median value
12
7
22,58 ± 5,45
9,71 ± 1,10
OS 0.034
IL17 ≤median value
>median value
11
8
14,54 ± 4,03
21,50 ± 5,35
OS 0.379
k-ras/mut Neutrophil Count ≤median value
>median value
9
9
7,77 ± 2,29
10,00 ± 3,04
OS 0.567
NLR ≤median value
>median value
8
10
10,75 ± 3,48
7,10 ± 1,70
OS 0.411
CRP ≤median value
>median value
9
9
12,55 ± 3,45
5,77 ± 1,88
OS 0.123
ENA ≤median value
>median value
11
7
11,48 ± 3,06
5,28 ± 0,91
OS 0.055
IL12 p70 ≤median value
>median value
5
10
7,60 ± 3,01
11,75 ± 3,26
OS 0.247
IL17 ≤median value
>median value
6
9
4,50 ± 2,46
14,27 ± 3,10
OS 0.010
Legend: OS, overall survival; NLR, Neutrophil/lymphocyte ratio; CRP, C-reactive protein; ENA, anti-extractable nuclear 
antigen; IFN ɣ, Interferon gamma; IL, interleukin.
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and micro-vascular damage [24]. A prolonged survival was 
found in patients who showed a progressive rise in 
peripheral CD3-CD56dimCD16brightNKs, a lymphocyte 
subset, which together with an antigen independent 
antitumor activity also holds the ability to promote an 
antigen specific T cell response stimulating the functional 
activity of peripheral DCs [25]. In our study, other 
parameters, including cytokines’ (TNFα, IL17/A, IL12/p70, 
IL10) and cell subsets’ (CD3+CD4+, CD3+CD8+, Tcms, Tems, 
Tregs, MDSCs) in peripheral blood, did not correlated with 
either PFS or OS on the whole population. Since 
experimental evidence suggests that alterations on k-ras 
pathway in CRC cells may have dramatic consequences 
within tumor micro-environment, involving inflammation, 
angiogenesis, and immune-response, we examined the 
predictive values of our markers in the two subsets of 
patients with k-ras/wt and k-ras/mut. The results showed 
that the inflammatory markers have a strict correlation with 
survival only in the k-ras/wt group, losing any statistical 
significance in patients with k-ras/mut. Interestingly, in the 
latter group of patients, the outcome was directly correlated 
to the baseline levels of IL17/A, an inflammatory cytokine 
able to amplify and empower the cytotoxic effects of pre-
existing CTLs in CRC tumor sites [26]. These 2 groups of 
patients did not show significant difference prior TSPP 
treatment with the exception of a much lower tumor 
infiltration by CD15+ inflammatory cells in the k-ras/mut 
group. This finding is suggestive of a different cancer 
associate-inflammatory profile within the tumor tissue with 
a different sensitivity to both cytotoxic stimula and 
cytotoxic effectors. In line with these findings, the 2 groups 
of patients presented a different immune-biological 
response to TSPP vaccination. In fact, patients with k-ras/
mut failed to induce auto-antibodies, such as cANCA and 
ENA, in response to TSPP vaccination, while their 
treatment was associated to increase in peripheral levels of 
IFNγ, IL17/A, and Tregs. In this context, IFNγ is an 
inflammatory cytokine, which is able to enhance the 
expression of PDL-1 on CRC cells and immune-cells in the 
tumor sites. This event potentially leads to empowerment of 
the PD-1/PDL1 immune-check point activity and 
neutralization of activated CTLs in the tumor. Additionally, 
and it is also known that IL17/A together with IFNγ 
promotes the switch of inactive Tregs to highly suppressive 
Tregs [27], which in turn, could affect the primary T cell 
response to TSPP vaccine of these patients. On the other 
hand, the results of other studies suggest that IL17/A 
production may also empower the cytotoxic activity of pre-
existing effector CTLs in the tumor site [28].This finding 
could also partially explain the predictive value of IL17/A 
baseline levels only in patients with k-ras/mut and in 
patients who receive TSPP vaccination and GOLFIG 
chemo-immunotherapy (Arm-C/DL0-3).
A number of studies have already, highlighted 
the detrimental effects of systemic inflammation in 
patients with different malignancies undergoing immune-
biological treatments [29–35]. Several studies, also 
suggest the existence of a strong link among angiogenesis, 
pro-inflammatory context and immune-editing within 
the tumor environment, which in turn could affect the 
responsiveness of the malignant cells to pro-apoptotic 
signals and immune-response [36].
These detrimental effects of cancer-associate 
inflammation are similar to those induced in the tumor 
Figure 3: Evaluation of predictive markers in mCRC patients with k-ras/wt and k-ras/mut who received TSPP vaccine. 
Different influence of baseline levels of NLR (A), CRP (B), ENA (C), IFNγ (D), IL12/p70 (E) and IL17/A (F) on k-ras wt and k-ras mut 
patients treated with TSPP vaccine. Overall survival was compared between the two groups of patients with baseline levels < and ≥ the 
median value of each specific parameter. Asterisk (*) represents statistical significance between the arms (P < 0.05).
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microenvironment by the presence of a malfunctioning 
k-ras pathway. In this context, it has been shown that 
the expression of activating k-ras mutation in CRC 
cells promotes the release pro-angiogenic factors, pro-
inflammatory cytokines, and chemokines, that in turn, 
make the tumor micro-environment able to protect the 
tumor by multiple pro-apoptotic stimula (cytotoxic drugs, 
anti-EGFR mAbs, CTLs, etc.) [37–43]. This hypothesis 
is in line with the finding that patients with k-ras/wt and 
k-ras/mut present a different immune-biological response 
to TSPP vaccination with a worse outcome. 
On these bases, we can conclude that the outcome 
of mCRC patients vaccinated with TSPP may be greatly 
hampered by their systemic inflammatory profile and by 
an altered k-ras pathway. This finding deserves further 
studies and must be taken into account in the design of 
future studies aimed to evaluate the antitumor activity of 
immunological strategies like TSPP vaccine in mCRC 
patients.
PATIENTS AND METHODS
The TSPP/VAC-1 is a phase Ib trial program 
designed to test in advanced cancer patients, the toxicity 
and immunological activity of TSPP in different 
therapeutic conditions,. The protocol consisted of three 
parallel and independent arms where TSPP vaccination 
was administered alone (arm-A) and in combination 
with the immune-adjuvant IG-1 regimen (arm-B) and in 
combination with the chemo-immunotherapy GOLFIG 
regimen (arm-C). The latter arm was reserved to mCRC 
patients and evaluated the effects of peptide vaccination, 
administered concomitantly (DL1-3) or after (DL0) 10/12 
GOLFIG courses. 
Ethical considerations and study design
The study was designed according to good clinical 
practice (GCP) recommendations. It was authorized by the 
Italian National Institute of Health (Istituto Superiore di 
Sanità), the Italian Ministry of Health, and approved by the 
University of Siena Ethical Committee Board (equivalent 
to Human Subject Committee of Investigational Review 
Board). The study registered with the TSPP/VAC-1 code 
(Eudract: # 2009-016897-33)was planned as a dose 
escalation trial, in three parallel and independent arms (A, 
B and C). TSPP dose-escalation was planned according to 
the Fibonacci’s series. The first cohort of patients received 
100 µg of peptide (DL1), the second, 200 µg (DL2), and 
the third 300 µg (DL3), every 21 days. New patients 
could be enrolled in higher dose level cohorts, only if 
no Grade IV event was demonstrated in patients treated 
with lower doses. Patients of arm A (8) received vaccine 
peptide alone, those of arm B (4) received TSPP and sc. 
GM-CSF (Sargramostim / Leukine®, Berlex, USA) (50 µg 
days 1–5) and sc. Aldesleukine/Proleukin®, Novartis, 
Switzerland (0.5 MIU bi-daily, days 6–15) according to 
the previously described IG-1 schedule [7]. Patients of 
arm C/DL1-3 (17) received peptide vaccination seven 
days after the beginning of the chemo-immunotherapy 
cycle with gemcitabine 1g/sqm on the day 1, oxaliplatin 
85 mg/sqm on the day 2, Levofolinic acid 100 mg/sqm 
on the days 1 and 2, bolus 5ʹ-FU 400 mg/sqm on days 1 
and 2 and infusional 5ʹ-FU 800 mg/sqm on days 1 and 
2, every 15 days according to the previously described 
GOLFIG [9–11]. These patients also received sc. GM-CSF 
(50 µg days 3–7) and sc. IL-2 (0.5 MIU bi-daily on days 
8–14 and 17–29). In particular, 17 patients of the latter 
group, received sc. TSPP vaccination at escalating dosage 
[3 patients entered the DL-1; 3, the DL-2; 11, the DL-3 
cohort] on biweekly bases, starting one week after each 
chemotherapy cycle (concomitant treatment). Other12 
patients received GOLFIG chemo-immunotherapy alone 
(DL0) for 10/12 courses and then maintenance therapy 
with the same schedule adopted for arm B (TSPP + IG1). 
Two patients of the DL0 group did not receive TSPP 
vaccination, due to early disease progression and decline 
in performance status, thus they were excluded by the 
statistical analysis. The remaining 10 patients entering 
the maintenance therapy group (DL0mant), received TSPP 
vaccination every 3 weeks (300 µg on the day 1), sc.GM-
CSF (50 µg at day, days 1–5 every 3 weeks), and sc.rIL2 
(0.5 MIU twice at day, days 6–15 every 3 weeks) [5, 6]. 
TSPP Vaccine
TSPP (YMIAHITGLFLDSLGFSTTLGDAHIYL) 
[4] was synthesized and characterized by good 
manufacturing practice (GMP) procedures by the American 
Peptide Ltd (Rockville, MD,USA). The aseptic vial filling 
process was performed by the Pharmacy of the Azienda 
Ospedaliera Universitaria Senese, which also performed 
the stability study, endotoxin evaluation and chemical 
related toxicity analysis of the product. TSPP was dissolved 
in DMSO and the exact peptide dose (100, 200 or 300 µg) 
was diluted with PBS in a volume of 250 µl, and then 1:2 
diluted with Montanide ISA 720 VG ST (Seppic, Milan, 
Italy) as adjuvant. The final volume of the vaccine was 
500 µl/dose. 
Patients’ population and study endpoints
Our analysis was performed on a sample of 41 
mCRC patients. The primary endpoints of the study were 
the identification of the maximal tolerated dose (MTD) 
and the most effective biological dose (MEBD) of TSPP 
peptide, by evaluating the frequency of adverse events 
per dose level and predefined immune-biological events 
in the three cohorts of patients. Evidence of anti-tumor 
activity was a secondary endpoint. The inclusion criteria 
were: written informed consent concerning treatment 
risk and biological monitoring, histological diagnosis of 
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malignant disease, at least two previous chemotherapy 
lines for advanced disease, measurable disease (according 
to WHO tumor response criteria), ECOG performance 
status ≤1, normal renal and hepatic functions, white blood 
cell count ≥2,500/mm3, hemoglobin levels ≥9 g/dl, platelet 
cell count ≥100,000/mm3, and normal heart function. The 
exclusion criteria were: any major organ failure, central 
nervous system involvement, second malignancies, active 
infectious disease, major inflammatory and autoimmune 
rheumatic diseases, and acquired immune-suppression. 
Treatment allocation was not masked. Standard clinical 
and laboratory evaluation (clinical history, physical 
examination, blood count and chemistry, serum dosage 
of C-reactive protein (CRP), erythrocyte-sedimentation 
rate (ESR), lactate dehydrogenase (LDH), rheumatoid 
factor, carcinoembryonic antigen (CEA) and CA19.9 
assays, chest x-rays and ultrasound abdominal scans, 
were performed at baseline and repeated every six weeks. 
Patients’ sera were tested for antinuclear antibodies 
(ANA) by IFA, (starting dilution 1:160) (SSA HEp2000, 
ImmunoConcepts); EliASymphony screening (Thermo 
Fisher Scientific); further ELiA tests were performed for 
single ANA specificities. ANCA, p-ANCA, and C-ANCA 
were measured by indirect immunofluorescence using 
INOVA substrate, while ENA was tested on Phadia250 
instrument. Contrast CT scans were scheduled every three 
months. Patients enrolled in the arm C/DL1-3 received 
combined TSPP/GOLFIG treatment for a maximal of 12 
cycles, then those who did not progress, received TSPP 
vaccination every 21 days at the dosage of 300 µg until 
disease progression, occurrence of unacceptable toxicity, 
clinical judgment, or withdrawal of consent. Any further 
treatment decision after disease progression was left to the 
physician in charge. Adverse events, toxicity and treatment 
response were evaluated according to WHO classification.
ELISA assays and multiplex analysis
Serum levels of Interferon(IFN)-ɣ, Tumor necrosis 
factor (TNF)-α, IL10, IL4, IL12/A, IL10 and IL17/A 
cytokines were measured using Bio-Plex human cytokine 
multiplex kits (Bio-Rad Inc., Hercules, CA). Briefly, 
a standard curve was created via dilution of premixed 
standards to 50,000 pg/ml, followed by serial dilution 
to 8 concentrations ranging from 32,000 to 1.95 pg/ml. 
The assay was performed in the 96-well filtration plate 
supplied with the Bio-Plex kit. Premixed beads coated 
with target antibodies (50 µl) were added to each well, and 
then washed twice with Bio-Plex wash buffer. Premixed 
standards or undiluted samples (50 µl) were then added 
to the wells, followed by shaking at 1,100 rpm for 30 sec 
and incubation for 30 min with shaking at 300 rpm at 
room temperature. Wells were then washed 3 times with 
Bio-Plex wash buffer, and 25 µl of the premixed detection 
antibodies was added to the wells. This was followed by 
shaking at 1,100 rpm for 30 sec and incubation for 30 min 
with shaking at 300 rpm at room temperature. Wells were 
again washed 3 times with Bio-Plex wash buffer, and 50 
µl of streptavidin-PE was added to the wells. This was 
incubated for 10 min with shaking at 300 rpm. Wells were 
washed 3 times with Bio-Plex wash buffer, and the beads 
were resuspended in 125 µl Bio-Plex assay buffer. The 
samples were then read using the Bio-Plex suspension 
array system. The fluorescence intensity of the beads was 
measured by using the Bio-Plex array reader. Bio-Plex 
Manager software with five-parametric-curve fitting was 
used for data analysis.
Fluorescence-activated cell sorting analysis 
of patient peripheral blood mononuclear cells 
(PBMC)
The patients’ PBMCs were purified by Ficoll-
Hypaque (Celbio S.P.A., Italy) gradient separation of 
buffy coats of heparinized blood samples and analyzed by 
Fluorescence-activated cell sorting (FACS) analysis, as 
described in previous studies [5, 6]. 
PBMC were stained with different pools of labeled 
monoclonal antibodies (mAbs) (CD4V450, CD45RAPE, 
CD62LFITC, CCR7PE-Cy7, Pharmingen;CD8PerCPCy 
5.5, CD45ROAPC, CD3FITC, CD19FITC, CD14FITC, 
CD11cAPC, CD16PE, Rat IgG2aFITC, Mouse IgG1, 
Becton Dickinson, Italy; CD56 APC, Mouse IgG2a 
APC Immunotools, DE; CD15 PE ABCam, UK; CD25 
PE, FoxP3 FITC, eBioscence, UK) and examined by a 
FACScalibur BD instrument. The fluorescent-minus-one 
and isotype control were included in each experiment in 
order to appropriately set the gates. Ki67 positive cells 
and Tregs were analyzed after intracellular immune-staining 
according to the manufacturer’s protocol (eBioscience). 
Cytofluorimetric analysis was carried out by using the 
FlowJo® software. The mean fluorescence intensity (MFI) 
and percent of positive expression (%) of each marker 
were measured. Results were expressed as fold induction 
relative to baseline indicated as 1.
Immunoistochemistry
immunohistochemistry was performed for TS 
expression in primary tumors and tumor infiltrating T 
cells expressing FoxP3 (Treg), CCR7 (Tcm/em), CD4, 
or CD8 and inflammatory cells expressing CD15. This 
analysis was carried out in the primary tumor of 41 
mCRC patients who received TSPP vaccine, whose 22 
with k-ras wt and 19 with mutated k-ras. In brief, sections 
were deparaffinized and peroxidase activity blocked. 
Antigen retrieval was performed with 1 mμ EDTA pH 
8.0, following which endogenous biotin was blocked 
by use of a commercial kit (Vector Laboratories, Inc., 
Burlingame, CA, USA) before incubation in 20% swine 
serum for 30 min. The primary antibody (#9718; Cell 
Signalling Technology, Inc., Danvers, MA, USA) was 
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added at a concentration of 1 : 100 and sections incubated 
overnight at 4° C. Sections were then incubated for 90 
min with a biotin-conjugated secondary antibody (Dako 
UK Ltd, Ely, UK) and for 45 min with streptavidin 
biotin-peroxidase conjugate (Vector Laboratories, Inc.). 
3,3′-diaminobenzidine tetrahydrochloride (DAB; Vector 
Laboratories, Inc.) was used as the chromogen. The 
numbers of positive stained cells in 15 separate high-
power fields (HPF; magnification ×20) were counted in 
a blinded manner. Results are expressed as number of 
positive cells per HPF.
Statistical analysis
Survival analysis and correlations between patient’s 
baseline characteristics and toxicity were evaluated by 
Kaplan Meier curves and Wilcoxon test statistic in the 
univariate analysis. All potential prognostic factors were 
transformed into categorical variables. Results were 
expressed as mean ± standard deviation (SD) of three 
determinations made in three different experiments, and 
analysed by the 2-tail Student’s t-test. A p-values ≤ 0.05 
were considered statistically significant. Variables with 
a p-value lower than 0.10 were used to construct the 
predictive models. These variables were entered into a 
multivariate analysis model according to Cox proportional 
hazard model to analyse the role of confounding factors, 
modelling the relationship among a set of one or more 
covariates and the hazard rate. The most significant 
variables were entered in the model through a step-wise 
method. Time variable contains the length of time during 
which a subject has been observed, representing a failure/
censor time. Overall survival (OS) was measured from the 
beginning of the treatment to the day of death from any 
cause. Progression-free survival (PFS) was calculated from 
the the beginning of the treatment to the day of local or 
distant recurrence or death from any cause. PFS and OS in 
particular, were correlated with selected immune-biological 
parameters with potential prognostic values. In order to 
perform the screening of these markers we evaluated the 
quantitative baseline values by dividing the patients in 
two groups according to the specific median value of each 
marker prior and after treatment and median post-treatment 
fold change to baseline values. Univariate analyses were 
conducted with the log-rank test and multivariate analyses 
with the Cox proportional hazard model. All survival data 
were analysed by using the SPSS software (version 23) and 
GraphPadInstat 3.2. statistical packages.
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